Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 15 07 2019
accepted: 18 09 2019
entrez: 26 10 2019
pubmed: 28 10 2019
medline: 29 10 2020
Statut: epublish

Résumé

Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although in the majority of cases this does not translate into a durable clinical response. However, DC vaccination is characterized by a robust safety profile, making this treatment a potential candidate for effective combination cancer immunotherapy. To explore this possibility, understanding changes occurring in the tumor microenvironment (TME) upon DC vaccination is required. In this line, quantitative and qualitative changes in tumor-infiltrating T lymphocytes (TILs) induced by vaccination with autologous tumor lysate/homogenate loaded DCs were investigated in a series of 16 patients with metastatic melanoma. Immunohistochemistry for CD4, CD8, Foxp3, Granzyme B (GZMB), PDL1, and HLA class I was performed in tumor biopsies collected before and after DC vaccination. The density of each marker was quantified by automated digital pathology analysis on whole slide images. Co-expression of markers defining functional phenotypes, i.e., Foxp3

Identifiants

pubmed: 31649669
doi: 10.3389/fimmu.2019.02353
pmc: PMC6794451
doi:

Substances chimiques

Cancer Vaccines 0

Banques de données

figshare
['10.6084/m9.figshare.c.4584041.v3']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2353

Informations de copyright

Copyright © 2019 Bulgarelli, Tazzari, Granato, Ridolfi, Maiocchi, de Rosa, Petrini, Pancisi, Gentili, Vergani, Piccinini, Carbonaro, Leone, Foschi, Ancarani, Framarini and Guidoboni.

Références

Clin Cancer Res. 2017 Sep 1;23(17):5024-5033
pubmed: 28512174
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Oncoimmunology. 2016 Feb 2;5(3):e1136044
pubmed: 27141370
Nat Rev Cancer. 2012 Mar 22;12(4):265-77
pubmed: 22437871
Clin Cancer Res. 2012 Mar 1;18(5):1386-94
pubmed: 22156613
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
Conf Proc IEEE Eng Med Biol Soc. 2011;2011:6162-5
pubmed: 22255746
BMJ Open. 2018 Aug 5;8(8):e021701
pubmed: 30082356
J Transl Med. 2013 May 31;11:135
pubmed: 23725550
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
J Immunol. 2008 Mar 1;180(5):3585-93
pubmed: 18292586
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Hum Vaccin Immunother. 2017 Nov 2;13(11):2575-2582
pubmed: 28362548
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Clin Cancer Res. 2016 Apr 15;22(8):1897-906
pubmed: 27084743
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Front Immunol. 2018 Oct 01;9:2265
pubmed: 30327656
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
JCI Insight. 2017 Apr 20;2(8):null
pubmed: 28422751
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
J Exp Med. 2005 Jan 17;201(2):249-57
pubmed: 15657294
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
J Cell Biol. 2010 May 31;189(5):777-82
pubmed: 20513764
Clin Cancer Res. 2014 May 15;20(10):2607-2616
pubmed: 24647571
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9
pubmed: 11531144
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
Melanoma Res. 2017 Aug;27(4):351-357
pubmed: 28654547
Cell Rep. 2017 Apr 4;19(1):203-217
pubmed: 28380359
J Transl Med. 2014 Jul 22;12:209
pubmed: 25053129
Cancer Res. 2010 Sep 15;70(18):7084-92
pubmed: 20823160
Cancer Res. 2010 Nov 1;70(21):8378-87
pubmed: 20861189

Auteurs

Jenny Bulgarelli (J)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Marcella Tazzari (M)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Anna Maria Granato (AM)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Laura Ridolfi (L)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Serena Maiocchi (S)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Francesco de Rosa (F)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Massimiliano Petrini (M)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Elena Pancisi (E)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Giorgia Gentili (G)

Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Barbara Vergani (B)

Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Milan, Italy.

Filippo Piccinini (F)

Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Antonella Carbonaro (A)

Department of Computer Science and Engineering (DISI), University of Bologna, Bologna, Italy.

Biagio Eugenio Leone (BE)

Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, Milan, Italy.

Giovanni Foschi (G)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Valentina Ancarani (V)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Massimo Framarini (M)

Advanced Oncological Surgery Unit, Morgagni-Pierantoni Hospital, Forlì, Italy.

Massimo Guidoboni (M)

Immunotherapy-Cell Therapy and Biobank Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH